Comparing the current results to its competitors, Tg Therapeutics Inc reported Revenue increase in the 2 quarter 2026 by 70.27 % year on year. The sales growth was above Tg Therapeutics Inc 's competitors' average revenue growth of 20.72 %, achieved in the same quarter.
Tg Therapeutics Inc 's Comment on Competition and Industry Peers
The company faces competition from third parties that may challenge or circumvent its patents or patent applications. Competitors may file U.S. patent applications claiming technology also claimed by the company, potentially resulting in interference proceedings to determine priority of invention. These proceedings can be costly. Additionally, lengthy development, testing, and regulatory review periods may cause patents to expire or have limited remaining life by the time products are commercialized, reducing the company's patent protection.
April 18, 2024
TG Therapeutics, Inc. recently announced the presentation of additional data on BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS) at two major neurology conferences. The ULTIMATE I and II Phase 3 trials and the ENHANCE Phase 3b trial evaluated the efficacy and safety of BRIUMVI in RMS patients. This article summarizes the key findings from these presentations and underscores the significance of BRIUMVI as a potential therapeutic option for individuals living with multiple sclerosis.The American Academy of Neurology (AAN) Annual Meeting:During the 2024 AAN Annual Meeting, held in Denver, Colorado, TG Therapeutics presented two additional data presentations from the ULTIMA...
April 15, 2024
TG Therapeutics Presents Positive Data for BRIUMVI (ublituximab-xiiy) in Multiple Sclerosis at AAN 2024 Annual MeetingTG Therapeutics, a leading biopharmaceutical company, made a significant announcement regarding the groundbreaking drug BRIUMVI (ublituximab-xiiy) during the 2024 American Academy of Neurology (AAN) annual meeting in Denver, Colorado. The company presented data from the ULTIMATE I and II Phase 3 trials, which showcased promising results for patients suffering from relapsing forms of multiple sclerosis (RMS). The event took place on April 15, 2024, and the link to the data presented is provided below. Furthermore, two more presentations are scheduled for Wednesday, April 17, 2024.During the pr...
January 9, 2024
In an announcement that holds the promise to magnetize significant attention in the field of biotechnology, TG Therapeutics, Inc. has avowed a worldwide licensing pact with Precision BioSciences, Inc. The focus of this strategic agreement is the development and commercialization of Precision s allogeneic Chimeric Antigen Receptor (CAR) T cell therapy program aimed at tackling autoimmune diseases. The timeline proposed for this task targets a United States Investigational New Drug (IND) filing in mid-2024. TG Therapeutics, a highly progressive biopharmaceutical company dedicated to developing innovative therapies for B-cell diseases, has secured exclusive rights to pioneer innovation by exploring the massive ...
Verastem Inc is a biopharmaceutical company that focuses on discovering and developing medicines to treat cancer by targeting the underlying biology of the disease. They employ a research-driven business model to identify novel therapeutic candidates, evaluate their potential through preclinical and clinical trials, and bring them to market with the goal of improving patient outcomes. Verastem emphasizes innovation, precision medicine, and strategic collaborations to advance their pipeline of cancer therapeutics.
Xencor Inc is a biotechnology company that primarily focuses on the development of therapeutic antibodies. Their business model revolves around utilizing their proprietary XmAb® technology to engineer antibodies with enhanced properties for the treatment of various diseases. They collaborate with pharmaceutical companies to develop and commercialize these antibody therapeutics, generating revenue through upfront payments, milestone payments, and royalties.
Zai Lab Limited operates as a biopharmaceutical company primarily in China. The company seeks to discover, develop, and commercialize innovative medicines to address unmet medical needs in the country. Zai Lab focuses on licensing and acquiring clinical stage or late-stage development drugs, and then progressing them through regulatory approval and commercial launch.
Sources:
Tg Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tg Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
